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The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), represents a public health crisis of major
proportions. Advanced age, male gender, and the presence of comorbidities have
emerged as risk factors for severe illness or death from COVID-19 in observation
studies. Hypertension is one of the most common comorbidities in patients with COVID-
19. Indeed, hypertension has been shown to be associated with increased risk for
mortality, acute respiratory distress syndrome, need for intensive care unit admission,
and disease progression in COVID-19 patients. However, up to the present time, the
precise mechanisms of how hypertension may lead to the more severe manifestations
of disease in patients with COVID-19 remains unknown. This review aims to present
the biological plausibility linking hypertension and higher risk for COVID-19 severity.
Emphasis is given to the role of the renin-angiotensin system and its inhibitors, given the
crucial role that this system plays in both viral transmissibility and the pathophysiology of
arterial hypertension. We also describe the importance of the immune system, which is
dysregulated in hypertension and SARS-CoV-2 infection, and the potential involvement
of the multifunctional enzyme dipeptidyl peptidase 4 (DPP4), that, in addition to the
angiotensin-converting enzyme 2 (ACE2), may contribute to the SARS-CoV-2 entrance
into target cells. The role of hemodynamic changes in hypertension that might aggravate
myocardial injury in the setting of COVID-19, including endothelial dysfunction, arterial
stiffness, and left ventricle hypertrophy, are also discussed.
Keywords: COVID, hypertension, renin-angiotensin system, hemodynamic factors, inflammation, dipeptidyl
peptidase 4
INTRODUCTION
The severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, named coronavirus disease
2019 (COVID-19), was initially described as a series of cases of atypical pneumonia arising in
Wuhan, China, in December 2019 (Zhu et al., 2020). The rapid spread of COVID-19 in many
countries worldwide has given rise to a global public health crisis of unprecedented proportions
in the modern era. As of October 9, 2020, the SARS-CoV-2 has infected 36,669,238 individuals,
with 1,063,863 deaths globally (Dong et al., 2020).
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The clinical spectrum of COVID-19 ranges from
asymptomatic infection to mild or moderate respiratory
and associated symptoms (cough, sore throat, nasal congestion,
myalgia, arthralgia, headache, shortness of breath) (Guan
et al., 2020b) to severe pneumonia accompanied by multiorgan
failure which may result in death. Accumulated evidence from
the first months of the COVID-19 pandemic has also linked
several risk factors with the development of severe morbidity
and mortality, such as advanced age, male gender, and the
coexistence of underlying chronic diseases. Indeed, the presence
of comorbidities, especially hypertension, have been consistently
reported as more common among patients with COVID-19 in
severe conditions, admitted to the intensive care unit (ICI), who
received mechanical ventilation or died, than among patients
with mild symptoms (Guan et al., 2020b; Wang et al., 2020; Wu
et al., 2020; Zhou et al., 2020a).
Hypertension represents one of the most prevalent
comorbidities in patients with COVID-19. Since the first
observational data available from China, in early March,
hypertension has emerged as a potential risk factor for COVID-
19 severity and mortality in different cohorts (Guan et al., 2020b;
Zhang et al., 2020; Zhou et al., 2020a). With the pandemic
progression worldwide, the association of hypertension and
unfavorable outcomes was also seen in other countries such
as Italy (Grasselli et al., 2020; Mancia et al., 2020) and the
United States (Garg et al., 2020). However, at present, the
precise impact of hypertension per se on COVID-19 severity
is yet to be defined. This review aims to present the biological
plausibility linking hypertension and higher risk for COVID-
19 severity. To this end, we discuss how cellular, molecular,
and functional alterations that underlie the pathophysiology
of hypertension can impact the severity of the SARS-CoV-2
infection, thereby predisposing hypertensive patients to more
complicated clinical outcomes.
ROLE OF THE RENIN-ANGIOTENSIN
SYSTEM (RAS)
The RAS is a key player both in the SARS-CoV-2 transmissibility
and in the pathophysiology of hypertension. It consists of a
complex network of precursors, enzymes, effector peptides, and
receptors that exerts a vital role in blood pressure control,
extracellular volume homeostasis, and cardiac function, among
several other physiological processes. Abnormal activation of
RAS components, ultimately leading to the upregulation of
angiotensin II (Ang II) and activation of its angiotensin II type 1
receptor (AT1R), contribute to the development and progression
of hypertension (Carson et al., 2001; Dahlof et al., 2002; Crowley
et al., 2005, 2006; Gurley et al., 2011).
Angiotensin-converting enzyme 2 (ACE2), a type I integral
membrane protein, is a homolog of angiotensin-converting
enzyme (ACE), the central enzyme of classical RAS (Tipnis
et al., 2000). ACE2 is expressed in organs that are important for
blood pressure control such as kidneys, vessels, brain, and heart,
where it hydrolyzes Ang II (Donoghue et al., 2000; Tipnis et al.,
2000). ACE2 is also found in the lungs, small intestine, ovaries,
and testicles (Tipnis et al., 2000). Additionally, ACE2 has been
identified as a functional receptor for the SARS-CoV-2 host cell
entry (Hoffmann et al., 2020) as well as for its predecessor SARS-
CoV (Kuba et al., 2005). Binding of the viral spike (S) protein
of the SARS-CoV-2 to the extracellular domain of ACE2 triggers
conformational changes that destabilize the membrane allowing
the internalization of the SARS-CoV-2 along with ACE2, leading
to ACE2 cell surface expression downregulation, viral replication
and cell-to-cell transmission (Heurich et al., 2014; Hoffmann
et al., 2020). During this process, the cleavage of the S protein by
host cell proteases, including the transmembrane serine protease
2 (TMPRSS2), is essential for viral infectivity (Iwata-Yoshikawa
et al., 2019). As such, TMPRSS2 constitutes a potential target for
the treatment of SARS-CoV-2 infected patients.
As a bioactive component of the RAS, ACE2 functions as
a counterregulatory enzyme, converting Ang II to Ang-(1-7).
This heptapeptide binds to the Mas receptor (MasR), modestly
reducing blood pressure, promoting vasodilation, increasing
excretion of sodium and water by the kidneys, and exerting anti-
inflammatory and antioxidant effects (Santos et al., 2018). These
actions are directly opposed to those induced by the activation
of the ACE/Ang II/AT1R axis. ACE converts Ang I to Ang
II, which in turn acts on the AT1R, increasing blood pressure,
inducing vasoconstriction, increasing renal tubular salt and water
reabsorption, and increasing the production of reactive oxygen
species (ROS) that promote inflammation and fibrosis (Benigni
et al., 2010). The ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR
pathways are co-expressed in most tissues and act in an autocrine
and paracrine manner. Thus, the balance between these pathways
determines, at least in part, whether or not tissue damage will
occur in response to pathological stimuli.
The kidney is a target for end-organ damage in hypertension,
plays an active role in the pathogenesis of hypertension, and it
is one of the sites of the highest levels of expression of ACE2
(Gembardt et al., 2005). Several studies have found that the
protein and mRNA abundance, as well as the activity of ACE2, are
reduced in the kidneys of experimental models of hypertension,
including spontaneously hypertensive rats, renin transgenic
hypertensive rats, aldosterone/NaCl-induced hypertension and
the model of 2 kidneys 1 clip (2K1C) hypertensive rats (Soler
et al., 2013). In mice on the C57BL/6 genetic background, (Gurley
et al., 2006) have found that ACE2 deficiency was associated
with a significant increase in blood pressure of ∼7 mmHg and
that the absence of ACE2 considerably enhanced the severity
of Ang II-dependent hypertension. Moreover, ACE2-deficient
mice chronically treated with Ang II infusion displayed a more
than 5-fold higher renal Ang II concentration than Ang II-
treated wild-type animals, thereby suggesting that the more
severe hypertension in ACE2-deficient mice may be attributed
to an impaired metabolism of Ang II in the kidney (Gurley
et al., 2006). Notably, Ang II upregulates ACE and downregulates
ACE2 expression in human proximal tubule cells via an AT1R-
mediated mechanism (Koka et al., 2008), thereby suggesting
that ACE and ACE2 may be regulated in a balanced manner,
which can be mediated via the local Ang II concentration.
This synergistic regulation is observed in renal biopsies from
humans, in which the ACE to ACE2 ratio is significantly higher in
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subjects with hypertension than in subjects without hypertension
(Wakahara et al., 2007). The human kidney is a target for the
SARS-CoV-2 infection (Braun et al., 2020; Puelles et al., 2020).
Acute kidney injury (AKI) has been observed in COVID-19
patients, and it is considered a marker of COVID-19 severity and
an adverse prognostic factor for survival (Cheng et al., 2020).
Renal Ang II overactivity in the setting of hypertension and
potentiated by SARS-CoV-2 induced ACE2 internalization, may
contribute to the pathogenesis of AKI in severely ill patients
with COVID-19. Favoring this hypothesis are the findings of
a prospective cohort study of 701 patients with COVID-19
conducted by Cheng et al. (2020). These authors investigated
the association between inpatient use of medications and the
development of AKI among patients with COVID-19. It was
observed that none of the patients who were taking RAS
inhibitors on admission or during hospitalization for COVID-19
developed AKI (Guan et al., 2020a).
Angiotensin-converting enzyme 2 expression is relatively
abundant in the heart, where it can be found in cardiomyocytes
endothelial cells, and fibroblasts (Santos et al., 2018). Crackower
et al. (2002) have found that ACE2 knockout mice display
increased heart content of Ang II and cardiac dysfunction
characterized by a decrease in fractional shortening with slight
ventricular dilation. Moreover, these authors have observed that
cardiac dysfunction of ACE2 knockout mice progressed with
age, and it was more pronounced in males than in females.
The fact that cardiac phenotype and increased Ang II levels
were completely reversible by deleting the ACE gene in ACE2
knockout mice strengths the notion that cardiac function is
modulated by the balance between ACE and ACE2, and that
the increase in local cardiac Ang II was involved in cardiac
impairment (Crackower et al., 2002). The cardiac effects of ACE2
remain under debate since ACE2 deletion mediated-cardiac
dysfunction was not observed by Gurley and colleagues. On the
other hand, it is well accepted that increased cardiac Ang II,
generated by cardiac ACE, drives left ventricular hypertrophy
(LVH) in multiple settings, including hypertension (Sadoshima
and Izumo, 1993; Crowley et al., 2006; Ainscough et al.,
2009). Therefore, patients with hypertension are particularly
susceptible to the imbalance between the ACE/Ang II/AT1R,
and ACE2/Ang-(1-7)/MasR, further intensified by myocardial
SARS-CoV-2-mediated ACE2 internalization (Huentelman et al.,
2005). Indeed, loss of surface ACE2 in cardiac cells may be
one of the underlying causes of acute, and perhaps long-term,
exacerbation of cardiovascular disease in hypertensive patients
infected with SARS-CoV-2.
Extrapolating data from SARS-CoV to SARS-CoV-2, one may
postulate that the imbalance in the signaling and actions of
products of ACE/ACE2, generated by the loss of ACE2 cell
surface expression due to SARS-CoV-2 infection, may lead to
severe acute respiratory failure in COVID-19 (Kuba et al., 2005).
The existence of a causal relationship between the imbalanced
ACE/ACE2 axis and the acute respiratory distress syndrome has
been established through the use of genetically modified animals
(Imai et al., 2005; Kuba et al., 2005). Imai et al. (2005) have
found that acute lung injury induced by acid aspiration results
in decreased expression of ACE2 and increased lung content of
Ang II in wild-type mice. Additionally, ACE2 knockout mice
with severe acute lung injury induced by acid aspiration or
sepsis displayed a higher rate of mortality and lung failure than
wild type mice with severe acute lung injury (Imai et al., 2005).
Conversely, the genetic deletion of ACE in ACE2 knockout
mice significantly attenuated these outcomes, demonstrating
that ACE/Ang II drive severe lung, whereas ACE2 protects
against it. The levels of ACE2 gene expression appear to be
upregulated in the lung of patients with pulmonary hypertension
when compared to controls (Pinto et al., 2020), however, to
our knowledge, the modulation of lung ACE to ACE2 ratio in
essential arterial hypertension remains elusive.
ROLE OF RAS INHIBITORS
During the early beginning of the COVID-19 pandemic, concerns
emerged that RAS inhibitors, cornerstone treatment of several
cardiovascular diseases, including hypertension, could promote
viral interaction with host cells, leading to increased cell entry,
viral replication and thereby COVID-19 exacerbation (Diaz,
2020; Esler and Esler, 2020). These concerns were primarily
based on findings that ACE inhibitors (ACEi) or angiotensin II
type 1 receptor (ARB) upregulate the expression and activity of
ACE2, the SARS-CoV-2 receptor, in the kidneys and heart of
experimental models of hypertension (Ferrario et al., 2005; Jessup
et al., 2006; Wang et al., 2016).
As the pandemic evolved, several observational studies
indicated that ACEi/ARBs use are not a risk factor for disease
severity and may actually be related to milder disease and better
outcomes (Supplementary Table S1) possibly by attenuating
the imbalance between ACE/Ang II/AT1R and ACE2/Ang-(1-
7)/MasR, reducing pathogenic inflammation and multiorgan
injury. Also, evidence from population studies suggests that RAS
inhibitors neither increase the risk of SARS-CoV-2 infection in
patients with hypertension nor negatively impact the disease
severity in those who are infected, establishing its safety
and reinforcing that they should not be switched/stopped
during the pandemic (Mancia et al., 2020; Mehta et al., 2020;
Reynolds et al., 2020).
Ongoing clinical trials will add crucial information on
the impact of RAS on COVID-19 severity. Currently, several
studies are registered in the clinicaltrials.gov platform aiming to
investigate the effects of ACEi/ARBs replacement or withdrawn
on patients with COVID-19 (Table 1), the impact of ACEi/ARBs
initiation in patients without hypertension on the risk of COVID-
19 infection and severity (Table 2) and whether modulation of
RAS by other agents with antihypertensive actions [AT1R biased
agonist, Ang-(1-7) analogs, DPP4 inhibitors or recombinant
ACE2] can impact COVID-19 outcomes (Table 3).
INFLAMMATION
There is strong evidence from human and experimental
studies to show that chronic hypertension accrues sustained,
low-grade inflammation, stimulating the adaptive immune
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system. This may reflect tissue damage as a consequence
of sustained high blood pressure, but experimental evidence
also points to the role of the immune system in the
generation of hypertension. Indeed, cells of the immune
system, which contribute importantly to normal blood pressure
homeostasis, may operate pathogenically in hypertension,
contributing to pressure-dependent and independent organ
damage (Mattson, 2019). Despite intense research, a unifying,
mechanistic understanding of the interaction in health and
disease has yet to emerge. The innate immune system has
some "protective" roles: macrophages, for example, regulate
extracellular fluid volume by buffering the release of salt
from the skin for renal excretion (Machnik et al., 2009).
Monocytes/macrophages can also scavenge reactive oxygen
species (Rosenblat et al., 2013) and have a role in clearing
vasoactive peptides such as endothelin-1 (Czopek et al., 2019),
influencing local vasomotor tone and blood pressure. Depletion
of monocytes/macrophages, or impairing their ability to clear
endothelin-1, increases blood pressure over a few days in
humans and mice (Guzik et al., 2007; Abais-Battad et al., 2018),
particularly in the setting of a pre-existing challenge to blood
pressure such as high salt or Ang II infusion. Conversely, T-cells
and B-cells depletion are protective, reducing hypertension and
vascular free-radical production in experimental models (Guzik
et al., 2007; Abais-Battad et al., 2018). Thus, these cells of
the adaptive immune system appear to be “pro-hypertensive”
and experimentally, re-population of the T-cell pool restores
the full hypertensive response to chronic Ang II infusion
(Fehrenbach et al., 2020). Mechanistically, high blood pressure
promotes T-cells activation, increasing their ability to invade
organs such as the kidney that are susceptible to barotrauma
(Itani et al., 2016). This invasive aspect appears to be directly
related to pressure, rather than hormonal aspects such as RAS
activation that may contribute to hypertension: preventing the
pressure rise significantly reduces T-cell and B-cell infiltration
(Shimada et al., 2020).
However, the picture is undoubtedly much more complex. For
example, in the long-term, reducing the ability of macrophages
to clear vasoactive endothelin-1 does not aggravate hypertensive
injury, but unexpectedly protects against end-organ damage.
This, in part, reflects the repolarizing of cells to an anti-
inflammatory phenotype (Guyonnet et al., 2020). The role of the
adaptive immune system is similarly, nuanced, and non-genomic
modifiers may influence the “pro-hypertensive” phenotype of the
T-cell (Seniuk et al., 2020).
Given the prevalence of hypertension in the general
population, it is not surprising that this is a common comorbidity
in patients hospitalized with coronavirus (Richardson et al.,
2020). However, pre-existing hypertension increases the risk
of developing severe disease and also of death (Zuin et al.,
2020). How hypertension causes poor clinical outcomes in
COVID-19 is not understood, but the intersection of blood
pressure homeostasis and the immune system may be important.
Certainly, SARS-CoV-2 infection features systemic inflammation
and accumulation of inflammatory cytokines, the extent of which
is strongly implicated in patient outcome (Huang et al., 2020).
Viral interaction with ACE2 provides a further pivot point for
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TABLE 2 | Ongoing randomized trials comparing ACEi/ARBs initiation to mitigate COVID-19 severity in patients with COVID-19.
Category NCT number Study design Acronym Intervention arm Study population Target
enrollment
Primary outcome
measure
ACEi
or
ARB initiation
ACEi/
ARB initiation
NCT04345406 Randomized, open-label N/A ACE inhibitors Patients with COVID-19
without contra-indication to
ACE inhibitors
60 Number of patients with
virological cure
NCT04366050 Randomized, double-blind,
placebo-controlled
RAMIC Ramipril 2.5 mg for 14 days Hospitalized patients or in a
emergency department
with COVID-19
560 Composite: death, need for
ICU admission or MV
NCT04355429 Randomized, open-label CAPTOCOVID Captopril 25 mg by nebulization Hospitalized patients with
COVID-19 needing oxygen
230 Ventilator free survival at
14 days
NCT04360551 Randomized, double-blind,
placebo controlled
N/A Telmisartan 40 mg Outpatients with COVID-19 40 Maximal clinical severity on
a seven-category ordinal
scale
NCT04335786 Randomized, double-blind,
placebo-controlled
PRAETORIAN-
COVID
Valsartan 80 to 160 mg titrated by
blood pressure
Hospitalized patients with
COVID-19
651 Composite: death,
mechanical ventilation or
ICU admission
NCT04394117 Randomized, single-blind
(outcomes assessor)
CLARITY Initiation of an ARB or switching from
non-RAAS inhibitor to ARB
Confirmed COVID-9 605 Improvement on a
seven-category ordinal
scale
NCT04340557 Randomized, open-label N/A Losartan 12.5 mg up titrated according
to BP
Hospitalized patients with
COVID-19 and mild to
moderate hypoxia
200 Need for MV
NCT04312009 Randomized, double-blind,
placebo-controlled
N/A Losartan 50 mg daily Hospitalized patients with
COVID-19 requiring oxygen
therapy
200 The difference in P/F ratio
at 7 days
NCT04343001 Randomized, factorial
design (2 × 2 × 2),
open-label
CRASH-19 Losartan 100 mg daily
Other interventions: Aspirin, Simvastatin
Hospitalized patients with
COVID-19
10000 Mortality up to 28 days
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TABLE 2 | Continued
Category NCT number Study design Acronym Intervention arm Study population Target
enrollment
Primary outcome
measure
NCT04328012 Randomized, double-blind,
placebo-controlled,
4 groups (parallel)
COVIDMED Losartan 25 mg daily
Other interventions: Lopinavir/Ritonavir,
Hydroxychloroquine
Hospitalized patients with
COVID-19
4000 The difference in the ordinal
scale of disease severity
NCT04359953 Randomized, open-label, 4
groups (parallel)
COVID-Aging Telmisartan 40 mg twice daily
Other interventions: Azithromycin,
Hydroxychloroquine
Hospitalized patients with
COVID-19 and age
≥75 years or ≥60 years if
dementia
1600 Mortality up to 14 days
NCT04351724 Randomized, open-label,
adaptative trial
ACOVACT RAS Blockade substudy Candesartan
4 mg daily, uptitrated
Other interventions: Chloroquine,
Lopinavir/Ritonavir, Rivaroxaban and
Clazakizumab
Hospitalized patients with
COVID-19 and blood
pressure ≥120/80 mmHg
500 Sustained clinical
improvement on a
seven-category ordinal
scale
NCT04356495 Randomized, open-label,
multi-arm multi-stage trial
COVERAGE Telmisartan 20 mg daily
Other interventions:
Hydroxychloroquine, Imatinib, and
Faviparavir
Outpatients with COVID-19 1057 Primary outcomes:
1- Mortality up to 14 days
2- Need for hospitalization
up to 14 days
NCT04447235 Randomized, double-blind,
placebo-controlled
TITAN Ivermectin plus Losartan 50 mg daily Cancer patients with
COVID-19
176 Composite: mortality, need
for MV or ICU admission up
to 28 days
NCT04311177 Randomized, double-blind,
placebo controlled
N/A Losartan 25 mg Symptomatic COVID-19
infection
516 Hospital admission up to
15 days
NCT04355936 Randomized, open-label N/A Telmisartan 80 mg twice daily COVID-19 infection 400 CRP at days 1.8 and 15
NCT04428268 Randomized, double-blind N/A Losartan 25 mg twice daily
Chloroquine vs. Chloroquine/Losartan
Hospitalized patients with
COVID-19
20 Mortality up to 28 days
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TABLE 3 | Ongoing clinical trials testing the hypothesis that modulation of RAS components can impact COVID-19 severity.
Category NCT number Study design Acronym Intervention arm Study population Target
enrollment
Primary outcome
measure
Recombinant ACE2 NCT04382950 Randomized, open-label N/A Recombinant ACE2
infusion plus
aerosolized
isotretinoin
Hospitalized patients with
COVID-19 and respiratory
failure
24 Fever
NCT04375046 Randomized, open-label Bacterial ACE2 Recombinant ACE2
infusion
Hospitalized patients with
COVID-19
24 (1) Fever
(2) Viral load
NCT04335136 Randomized, double-blind,
placebo-controlled
APN01-COVID-19 Recombinant ACE2
infusion
Hospitalized patients with
COVID-19
200 Composite: death or
mechanical ventilation up to
28 days or hospital
discharge
Biased agonist of
AT1R
NCT04419610 Randomized, double-blind,
placebo-controlled
N/A TRV027 at
12 mg/hour until
discharge or 7 days
Hospitalized patients with
COVID-19
60 Mean change from baseline
D-dimer at day 8
Ang 1-7 analogs NCT04332666 Randomized, double-blind,
placebo controlled
ATCO Angiotensin-(1-7)
infusion (venous) of
0.2 mcg/Kg/h for
48h
Hospitalized patients with
COVID-19 respiratory failure
and MV
60 Composite: mortality and
MV-free days
NCT04375124 Non-randomized, open label N/A angiotensin peptide
(1-7) derived
plasma
Hospitalized patients with
COVID-19
20 Mortality up to 4 months
NCT04401423 Randomized, double-blind,
placebo-controlled
TXA COVID-
19 Clinical
Trial
TXA127 0.5 mg/kg
per day
Hospitalized patients with
COVID-19 requiring oxygen
therapy
100 1-Acute kidney injury up to
7 days
2-Need for VM up to 7 days
DPP4 inhibitors NCT04341935 Randomized, open-label N/A Linagliptin 5 mg
daily
Hospitalized patients with
COVID-19
20 Changes in glucose levels
NCT04371978 Randomized, open-label N/A Linagliptin 5 mg
daily
Hospitalized patients with
COVID-19
100 Time to clinical
improvement (WHO scale
of COVID-19)
Ang-1-7, Angiotensin-1-7; AT1R, Angiotensin II type 1 Receptor; DPP4, Dipeptidyl peptidase 4.
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local inflammation since ACE2 converts pro-inflammatory Ang
II to Ang-(1-7), which has anti-inflammatory roles. It is evident
that the inflammation response to COVID-19 is amplified in
hypertensives compared to normotensive controls (Yang et al.,
2020). In humans, high levels of systemic inflammation driven by
infection induce a short-lived, extensive endothelial dysfunction
(Hingorani et al., 2000) that would be anticipated to transiently
increase cardiovascular risk. It is not difficult to imagine that
this risk would be exaggerated for individuals with a vulnerable
cardiovascular system, such as those with hypertension. Of
importance, in patients receiving antihypertensive medicines,
those on ACEi or ARBs had reduced levels of inflammatory
biomarkers (C-reactive protein and procalcitonin) and better
outcomes than those on other antihypertensive medication (Yang
et al., 2020). These outcomes from a retrospective, single-center
cohort (Wuhan, China) study give some insight suggesting that
immune system/blood pressure interactions are important for
COVID-19 severity, and also that ACEi, may have beneficial
cardiovascular effects in this setting beyond blood pressure
control. Indeed, targeting excessive inflammation is an attractive
strategy to improve the health of the arterial cardiovascular
system (Zanoli et al., 2020) and may be particularly relevant in
understanding cardiovascular risk in COVID-19.
HEMODYNAMIC FACTORS
Endothelial Dysfunction
Endothelial cells play a vital role in cardiovascular homeostasis
by controlling vasomotor tone, maintaining vascular integrity,
exerting barrier protecting effects, and preventing platelet and
leukocyte adhesion and aggregation (Deanfield et al., 2007).
It also regulates fibrinolysis and the coagulation cascade,
provides antiproliferative and anti-inflammatory actions, and
protects against oxidative stress (Deanfield et al., 2007). In
turn, abnormalities of the vascular endothelium significantly
contribute to a plethora of cardiovascular disorders.
A large body of evidence demonstrates the presence of
endothelial dysfunction in patients with hypertension (Watson
et al., 2008). Endothelial dysfunction is characterized by
imbalanced vasodilation and vasoconstriction, elevated ROS and
pro-inflammatory mediators, as well as reduced bioavailability of
nitric oxide (NO) (Deanfield et al., 2007; Watson et al., 2008).
As aforementioned, Ang II, via AT1R, is a potent activator of
oxidative and inflammatory cascades, the primary mediators
of endothelial dysfunction. Under physiological conditions,
however, the ACE2/Ang-(1-7)/MasR axis stimulates the activity
of the endothelial NO synthase, increasing NO production.
Adding up to this effect, Ang-(1-7) decreases the activity of
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
stimulated by Ang II, directly modulating the generation of
reactive ROS (Sampaio et al., 2007).
Many severe COVID-19 patients show signs of a cytokine
storm that could be aggravated due to overactivation of
Ang II, increased production of ROS, and a preexistent pro-
inflammatory state, features of hypertension associated-chronic
endothelial dysfunction. In fact, endotheliitis and an increase in
D-dimer (a marker of activation of coagulation and fibrinolysis)
have been described in the pathological findings of patients with
COVID-19 (Tang et al., 2020; Varga et al., 2020). Therefore, it is
plausible to postulate that circulating SARS-CoV-2 may interact
with endothelial cells of hypertensive patients culminating both
in direct viral injury and in a dysfunctional response to infection,
amplificating chemokine release, inflammatory cell adhesion and
migration through the endothelial barrier, ultimately leading to
a procoagulant state and tissue damage (i.e., myocardial injury,
acute respiratory distress syndrome) (Ackermann et al., 2020;
Bermejo-Martin et al., 2020).
Arterial Stiffness
Arterial stiffness describes the reduced capability of an artery
to expand and contract in response to pressure changes. It
is measured by carotid-femoral pulse wave velocity and is
an independent predictor of cardiovascular (CV) events and
mortality in patients with hypertension (Laurent et al., 2001).
Potentially, high arterial stiffness could have deleterious
effects in patients with SARS-CoV-2 infection thorough different
putative mechanisms: (i) chronically, arterial stiffness can
increase the energy penetration of the increased pulsatile flow
from the larger arteries, damaging target organs (brain, kidney,
heart) and aggravating the infection by mitigating the functional
reserves of different systems; (ii) the COVID-19 cytokine-storm
may cause ventricular-arterial decoupling in the setting of low
systemic vascular resistance and elevated heart rate. In this
scenario, patients with high arterial stiffness could be more
prone to ventricular-arterial decoupling by increasing pulsatile
components of the total arterial load to the left ventricle (LV):
proximal aortic impedance, wave reflections and arterial tree
compliance (Chirinos et al., 2014, 2019; Ikonomidis et al., 2019)
which ultimately leads to increased myocardial oxygen demand,
CV inefficiency, and left ventricle (LV) energetic failure (Chemla
et al., 2003; Guarracino et al., 2014); and (iii) increased arterial
stiffness is associated with reduced coronary flow reserve in
hypertensive patients (Ikonomidis et al., 2008) and lower diastolic
blood pressure (coronary perfusion pressure), rendering these
patients more vulnerable to myocardial injury and ischemia - a
known complication of COVID-19 (Hendren et al., 2020).
Another intriguing aspect warranting exploration is whether
survivors of COVID-19 will develop long term vascular sequelae
of the infection, such as increased arterial stiffness and
accelerated vascular aging. The Artery Society recently launched
a collaborative, multicenter, research project to evaluate the
vascular impact of the infection1 and will periodically test
different biomarkers of aging in patients that had COVID-19.
Left Ventricle Hypertrophy
Prolonged systemic hypertension results in hypertensive target-
organ damage, and the most common manifestation of this
is left ventricular hypertrophy (LVH). LVH - due to cellular
hypertrophy and expansion of extracellular matrix - is defined
as an increase in the mass of the left ventricle secondary
to chronically elevated afterload and neurohormonal stimuli
1http://www.arterysociety.org/our-activities/cartesian-2/
Frontiers in Physiology | www.frontiersin.org 8 November 2020 | Volume 11 | Article 599729
fphys-11-599729 November 13, 2020 Time: 14:23 # 9
Tavares et al. Hypertension and COVID-19 Severity
(Diez and Frohlich, 2010). Arterial stiffness plays a major role
in LVH as it accelerates pulse wave velocity, causing premature
arrival of wave reflections to the central aorta and by producing
amplification of the mid-to-late systolic pressure, chronically
stressing the LV (Chirinos et al., 2019). Allied to neurohormonal
stimuli, both processes generate a series of molecular, cellular, and
structural adaptations leading to cardiac remodeling (Nwabuo
and Vasan, 2020). LVH is not only a marker of hypertension-
related target organ damage but also an independent risk factor
for CV complications (Haider et al., 1998; Sundstrom et al., 2001;
Narayanan et al., 2014; Bang et al., 2017; Afify et al., 2018) that can
occur after weaning of the initial compensatory mechanism due
to contractile, electrical, structural or metabolic abnormalities
(Pitoulis and Terracciano, 2020).
Myocardial injury among patients hospitalized with COVID-
19 has been described since the early reports of the disease
(Zhou et al., 2020a). Although being an important prognostic
factor in severe cohorts (Guo et al., 2020; Lala et al., 2020;
Shi et al., 2020a,b), the exact mechanism of myocardial injury
is not fully understood as multiple plausible mechanisms
often coexist in a single patient including multiorgan failure,
types 1 and 2 myocardial infarction, disseminated intravascular
coagulation, endothelial cell dysfunction, pre-existing chronic
injury, pulmonary hypertension, among others (Jaffe et al.,
2020). It is also unknown if there is a causal relationship
between myocardial injury and disease severity or if it is solely
a marker of pre-existing cardiovascular disease. LVH-related
changes in the myocardial tissue and extracellular matrix might
be related to both an increased risk of myocardial injury due
to several pathophysiological pathways (increased cardiac Ang
II, endothelial dysfunction, chronic inflammation, upregulated
cardiac DPP4 expression) and an abolished cardiovascular
response to the stress related to the infection.
Left ventricular hypertrophy imposed changes of cardiac
structure function can complicate further the management of
these patients in the intensive care unit (ICU), as LV compliance
and diastolic function are impaired: the rise in the end-diastolic
pressure narrows the optimal volume status for hemodynamic
stability without pulmonary congestion (Sanfilippo et al., 2018);
sinus tachycardia or supraventricular arrhythmias with rapid
ventricular response can trigger hemodynamic collapse by
reduced LV filling time-related to increase in the heart rate
(Borlaug et al., 2011); increased LV filling pressure is also an
independent risk factor for weaning failure from mechanical
ventilation (Papanikolaou et al., 2011; Konomi et al., 2016; Liu
et al., 2016) and the use high positive end-expiratory pressure
during mechanical ventilation can lead to additional impairment
in LV relaxation (Chin et al., 2013; Juhl-Olsen et al., 2013).
Also, the electrical remodeling due to LVH in hypertensive
patients might be related to an increased risk of malignant
ventricular arrhythmias and sudden cardiac death (Aro and
Chugh, 2016), as they are being treated in the ICU with other
aggravating factors such as mechanical ventilation, vasoactive
drugs, medications that prolong the QT interval, and electrolyte
disturbances. This overlap of hemodynamics and electrical
disorders reflecting cellular and molecular remodeling due to
LVH can indeed be the cause of poorer outcomes in patients with
COVID-19 being treated in the ICU and poises a great challenge
for clinicians that need to untangle the complexity of a serious
illness aggravated by pre-existing conditions.
ROLE OF DIPEPTIDYL PEPTIDASE 4
(DPP4)
Bioinformatic approaches based on protein crystal structure
predicted that the middle east respiratory syndrome coronavirus
(MERS-CoV) receptor DPP4 displays a high affinity with the
SARS-CoV-2 spike protein (Li et al., 2020). This thereby suggests
that SARS-CoV-2 may utilize DPP4 as a coreceptor, in addition
to ACE2, to gain entry into the host cell. Nevertheless, the
results of free energy calculation revealed that SARS-CoV-2 spike
protein binds ACE2 with higher affinity than that of DPP4 (Li
et al., 2020). Moreover, it was shown that only Hela and baby
kidney hamster (BHK2) cells transfected with human ACE2,
but not with human DPP4, were capable of being infected with
SARS-CoV-2 (Hoffmann et al., 2020; Letko et al., 2020; Zhou
et al., 2020b). However, further research is necessary to defined
whether or not DPP4 may mediate the SARS-CoV-2 entry into
permissive cells.
Dipeptidyl peptidase is a serine peptidase expressed on the
surface of several cell types, including epithelial and endothelial
cells and lymphocytes (Kenny et al., 1976; Marguet et al., 2000;
Lambeir et al., 2003). It also exists as a soluble circulating form
in plasma and other body fluids (Lambeir et al., 2003). Through
its enzymatic function, DPP4 modulates the biological activity
of several circulating hormones, neuropeptides, cytokines, and
chemokines. In addition to its peptidase, activity DPP4 interacts
with several proteins, including the renal proximal tubule
Na+/H+ exchanger isoform 3 (NHE3) (Girardi et al., 2001),
fibronectin and collagen, adenosine deaminase (ADA), C-X-
C chemokine receptor type 4, underscoring the potential role
of DPP4 in sodium retention, fibrosis, and inflammation. The
importance of DPP4 for the scientific and medical community
has considerably raised since the approval of inhibitors of
DPP4 activity, known as gliptins, for the treatment of type
2 diabetes (T2D).
The gliptins do not bind to the putative receptor binding site
of SARS-CoV-2 (Li et al., 2020). However, it does not exclude
the possibility that DPP4 inhibition may indirectly attenuate
the severity of COVID-19, due to the role that DPP4 plays
in the pathophysiology of common comorbidities in patients
with COVID-19 (Ryskjaer et al., 2006; Dos Santos et al., 2013;
Zhong et al., 2013), including hypertension. Indeed, successive
clinical studies have demonstrated that gliptins confer renal and
cardiovascular benefits in patients with hypertension with or
without T2D (Nistala and Savin, 2017). Intriguingly, although
known primarily for its role as competitive inhibitors, gliptins are
also capable of reducing DPP4 protein and mRNA abundance
in the heart, kidneys, and endothelial cells of experimental
animals of cardiovascular and metabolic diseases (Dos Santos
et al., 2013; Kanasaki et al., 2014; Arruda-Junior et al., 2016;
Beraldo et al., 2019). Whether altered DPP4 expression in
the setting of hypertension, as well as of other comorbidities,
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contributes to SARS-CoV-2 infectivity, and COVID-19 severity
is currently undetermined.
Recent evidence suggests the existence of an interplay
between DPP4 and tissue RAS (Aroor et al., 2016; Beraldo
et al., 2019). In renal proximal tubule cells, Ang II, through
AT1R, enhances DPP4 activity, whereas inhibition of DPP4
mitigates Ang II-mediated activation of AT1R signaling and its
downstream effects (Aroor et al., 2016). In rats with chronic
kidney disease (CKD) and hypertension, the administration of
the DPP4 inhibitor sitagliptin ameliorated hypertension, kidney
function and restored the cardiac ratio of Ang II to Ang-(1-
7) concentrations in the heart by reducing the levels of Ang
II and increasing the content of Ang-(1-7) (Beraldo et al.,
2019). Interestingly, sitagliptin was capable of upregulating ACE2
expression in the heart of rats with CKD and as well as in
control animals (Beraldo et al., 2019). In line with these findings,
Zhang et al. (2015) found that the DPP4 inhibitor linagliptin
lowered the expression of the AT1R and upregulated the activity
of ACE2 in the heart in rats with Ang II-induced hypertension.
Collectively, these studies support the hypothesis that increased
DPP4 activity and expression can favor an imbalance between
ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR.
The vascular activity and expression of DPP4 are increased
in hypertensive rats (Linardi et al., 2004; Savignano et al.,
2017), suggesting that this peptidase may contribute to
impaired vascular function associated with high blood pressure.
Accordingly, extensive studies have shown that DPP4 inhibitors
play a protective effect against hypertension-related vascular
events, such as endothelial dysfunction and increased arterial
stiffness (Kishimoto et al., 2019; Zhang et al., 2019). The
vasoprotective effects of DPP4 inhibition are mediated through
multiple mechanisms, including improved NO bioavailability
by upregulation of endothelial NOS, and thus, endothelium-
dependent relaxation; reduction of ROS generation, and
cyclooxygenase-2 expression; as well as by suppression of
inflammatory responses (Zhang et al., 2019; Liu et al., 2020).
Several studies have demonstrated that DPP4 inhibitors
ameliorate LVH (Dos Santos et al., 2013; Arruda-Junior
et al., 2016; Beraldo et al., 2019; Nakajima et al., 2019;
Nam et al., 2019; Okabe et al., 2020), whereas upregulated
activity and expression of heart DPP4 is associated with
cardiac remodeling and dysfunction (Dos Santos et al.,
2013; Arruda-Junior et al., 2016; Beraldo et al., 2019). The
antihypertrophic effects of the DPP4 inhibitor teneligliptin
have been recently unraveled in an experimental model
of Ang II-induced hypertension (Okabe et al., 2020). The
authors found that the administration of teneligliptin to
C57BL/6J mice suppressed Ang II-induced NADPH oxidase
4 mRNA overexpression, ROS production, and attenuated
LVH without affecting blood pressure (Okabe et al., 2020).
DPP4 inhibition has also mitigated LV remodeling and
dysfunction in other experimental models of hypertension, such
as spontaneously hypertensive rats and Dahl salt-sensitive rats
(Nakajima et al., 2019; Nam et al., 2019). However, in the
FIGURE 1 | Putative mechanisms linking hypertension and COVID-19 severity. Patients with hypertension are more prone to a vicious interplay between RAS
imbalance, chronic low-grade inflammation, and elevated DPP4 activity and expression. Dysregulation of these biological processes may be aggravated by the
SARS-CoV-2 infection, giving rise to an exacerbated immune response that culminates in tissue damage/dysfunction. Also, end-organ damage caused by chronic
hypertension diminishes cardiovascular reserve, as arterial stiffening, endothelial dysfunction and left ventricular hypertrophy emerges, leading to synergic processes
that increase the susceptibility to know complications of COVID-19 including myocardial injury and ischemia, acute lung injury, thrombosis, acute kidney injury,
ventricular arrhythmias and potentially death. AKI, acute kidney injury; CV, cardiovascular; CVD, cardiovascular disease; DPP4, dipeptidyl peptidase 4; LV, left
ventricle; LVH, left ventricular hypertrophy; RAS, renin-angiotensin system; ROS, reactive oxygen species; VA, ventricle-atrial.
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latter two studies, the gliptin-induced amelioration of cardiac
remodeling and dysfunction was accompanied by blood pressure
lowering effects.
CONCLUDING REMARKS
The relationship between hypertension, SARS-CoV-2 infection,
and tissue injury is complex and multifactorial. Untangling
the importance of several pathophysiological mechanisms in
COVID-19 severity is still a work in progress, as scientific
and clinical knowledge is continually being updated during the
current pandemic. Through putative cellular, molecular and
functional mechanisms, we provide a conceptual framework
on how these biological processes may interact and lead to
COVID-19 severity in patients with pre-existing hypertension:
the role of the RAS, inflammation, endothelial dysfunction,
arterial stiffness, left ventricular hypertrophy and DPP4 are
summarized in Figure 1. In brief, patients with hypertension
can be more prone to RAS imbalance, which in turn lead
to vasoconstriction/inflammation due to unopposed Ang II
effect, aggravated by increased DPP4 vascular activity/expression
and by chronic low-grade inflammation. This dysregulated
response, allied with diminished physiologic cardiovascular
reserve induced by hypertension - arterial stiffening, left
ventricular hypertrophy and endothelial dysfunction – creates
the perfect milieu for both COVID-19 related tissue injury and
worsening of cardiac, renal and vascular function.
Targeting these biological processes might attenuate the
inflammatory response, reduce tissue injury, and ultimately
lead to better outcomes in hypertensive patients with SARS-
CoV-2 infection. Also, understanding the pathophysiology of
hypertension in cardiovascular hemodynamics and how it might
lead to poor outcomes in COVID-19 patients can aid the clinician
in making decisions at the bedside. Finally, the role of RAS
inhibitors needs to be further investigated, but, to the best of
our knowledge, there is no known harmful impact of these
medications neither on the risk of infection or disease severity.
Noteworthy, preliminary data suggest that these antihypertensive
agents may, in fact, confer a protective effect.
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